External Quality Assessment 2.0: The Importance of a Standardized Implementation of TILs for Daily and Trial Practices
Simple Summary
Author Contributions
Funding
Conflicts of Interest
References
- Denkert, C.; Von Minckwitz, G.; Darb-Esfahani, S.; Lederer, B.; Heppner, B.I.; Weber, K.E.; Budczies, J.; Huober, J.; Klauschen, F.; Furlanetto, J.; et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: A pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018, 19, 40–50. [Google Scholar] [CrossRef]
- Loi, S.; Adams, S.; Schmid, P.; Cortés, J.; Cescon, D.W.; Winer, E.P.; Toppmeyer, D.L.; Rugo, H.S.; De Laurentiis, M.; Nanda, R.; et al. Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086. Ann. Oncol. 2017, 28, v608. [Google Scholar] [CrossRef]
- Amgad, M.; Stovgaard, E.S.; Balslev, E.; Thagaard, J.; Chen, W.; Dudgeon, S.; Sharma, A.; Kerner, J.K.; Denkert, C.; Yuan, Y.; et al. Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. npj Breast Cancer 2020, 6, 16. [Google Scholar] [CrossRef] [PubMed]
- Salgado, R.; Denkert, C.; Demaria, S.; Sirtaine, N.; Klauschen, F.; Pruneri, G.; Wienert, S.; Van den Eynden, G.; Baehner, F.L.; Penault-Llorca, F.; et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILs Working Group 2014. Ann. Oncol. 2015, 26, 259–271. [Google Scholar] [CrossRef] [PubMed]
- Denkert, C.; Wienert, S.; Poterie, A.; Loibl, S.; Budczies, J.; Badve, S.; Bago-Horvath, Z.; Bane, A.; Bedri, S.; Brock, J.; et al. Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: Results of the ring studies of the international immuno-oncology biomarker working group. Mod. Pathol. 2016, 29, 1155–1164. [Google Scholar] [CrossRef] [PubMed]
- Brown, L.C.; Salgado, R.; Luen, S.J.; Savas, P.; Loi, S. Tumor-Infiltrating Lymphocyctes in Triple-Negative Breast Cancer: Update for 2020. Cancer J. 2021, 27, 25–31. [Google Scholar] [CrossRef] [PubMed]
- Boursier, G.; Vukasovic, I.; Brguljan, P.M.; Lohmander, M.; Ghita, I.; Andreu, F.A.B.; Barrett, E.; Brugnoni, D.; Kroupis, C.; Sprongl, L.; et al. Accreditation process in European countries—An EFLM survey. Clin. Chem. Lab. Med. (CCLM) 2016, 54, 545–551. [Google Scholar] [CrossRef] [PubMed]
- Berner, E.S. Diagnostic Error in Medicine: Implications for Clinical Laboratory Scientists. Ann. Clin. Lab. Sci. 2017, 47, 649–656. [Google Scholar] [PubMed]
- Standardization IOf ISO15189: 2012; Medical Laboratories—Requirements for Quality and Competence. The International Organization for Standardization: Geneva, Switzerland, 2012.
- Tack, V.; Schuuring, E.; Keppens, C.; Hart, N.; Pauwels, P.; Van Krieken, H.; Dequeker, E.M. Accreditation, setting and experience as indicators to assure quality in oncology biomarker testing laboratories. Br. J. Cancer 2018, 119, 605–614. [Google Scholar] [CrossRef] [PubMed]
- Keppens, C.; De Smedt, J.; Mc Dequeker, E. Implementation of Novel Methods, Markers or Sample types in Molecular Pathology–Quality Assurance Aspects. Arch. Clin. Biomed. Res. 2020, 4, 302–324. [Google Scholar] [CrossRef]
- Salgado, R.; Bellizzi, A.M.; Rimm, D.; Bartlett, J.M.S.; Nielsen, T.; Holger, M.; Laenkholm, A.-V.; Quinn, C.; Cserni, G.; Cunha, I.W.; et al. How current assay approval policies are leading to unintended imprecision medicine. Lancet Oncol. 2020, 21, 1399–1401. [Google Scholar] [CrossRef]
- Hoda, R.S.; Brogi, E.; D’Alfonso, T.M.; Grabenstetter, A.; Giri, D.; Hanna, M.G.; Kuba, M.G.; Murray, D.M.P.; Vallejo, C.E.; Zhang, H.; et al. Interobserver Variation of PD-L1 SP142 Immunohistochemistry Interpretation in Breast Carcinoma: A Study of 79 Cases Using Whole Slide Imaging. Arch. Pathol. Lab. Med. 2021, 145, 1132–1137. [Google Scholar] [CrossRef] [PubMed]
- Emens, L.; Molinero, L.; Loi, S.; Rugo, H.S.; Schneeweiss, A.; Diéras, V.; Iwata, H.; Barrios, C.H.; Nechaeva, M.; Duc, A.N.; et al. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. J. Natl. Cancer Inst. 2021, 113, 1005–1016. [Google Scholar] [CrossRef] [PubMed]
- Gonzalez-Ericsson, P.I.; Stovgaard, E.S.; Sua, L.F.; Reisenbichler, E.; Kos, Z.; Carter, J.M.; Michiels, S.; Le Quesne, J.; Nielsen, T.O.; Lænkholm, A.V.; et al. The path to a better biomarker: Application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice. J. Pathol. 2020, 250, 667–684. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Nauwelaers, I.; Laudus, N.; Peeters, D.; Acs, B.; Denkert, C.; Michiels, S.; Horlings, H.; Siziopikou, K.P.; Ely, S.; Zardavas, D.; et al. External Quality Assessment 2.0: The Importance of a Standardized Implementation of TILs for Daily and Trial Practices. Cancers 2022, 14, 3762. https://doi.org/10.3390/cancers14153762
Nauwelaers I, Laudus N, Peeters D, Acs B, Denkert C, Michiels S, Horlings H, Siziopikou KP, Ely S, Zardavas D, et al. External Quality Assessment 2.0: The Importance of a Standardized Implementation of TILs for Daily and Trial Practices. Cancers. 2022; 14(15):3762. https://doi.org/10.3390/cancers14153762
Chicago/Turabian StyleNauwelaers, Inne, Nele Laudus, Dieter Peeters, Balazs Acs, Carsten Denkert, Stefan Michiels, Hugo Horlings, Kalliopi P. Siziopikou, Scott Ely, Dimitrios Zardavas, and et al. 2022. "External Quality Assessment 2.0: The Importance of a Standardized Implementation of TILs for Daily and Trial Practices" Cancers 14, no. 15: 3762. https://doi.org/10.3390/cancers14153762